800px-paracetamol_acetaminophen_500_mg_pills

MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination

pharmafile | June 18, 2019 | News story | Manufacturing and Production Contamination, MHRA, fungal, paracetamol, pharma 

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.

The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.

A number of tablets in each batch were found to be discoloured due to the fungal contamination.

However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.

Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.

Louis Goss

Related Content

headache

AbbVie’s Aquipta receives MHRA marketing authorisation

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

Latest content